5-溴吲哚-3-乙酰胺 | 196081-79-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-溴吲哚-3-乙酰胺
• 中文别名: 5-溴吲哚-3-乙胺
• 英文名称: 2-(5-bromo-1H-indol-3-yl)acetamide
• 英文别名: 5-bromoindole-3-acetamide；2-(5-bromo-1H-indol-3-yl)-acetamide
• CAS: 196081-79-5
• 化学式: C₁₀H₉BrN₂O
• mdl: MFCD00022752
• 分子量: 253.098
• InChiKey: DVPBWLLOGOINDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3
• 海关编码：
  2933990090
• 安全说明：
  S22,S24/25
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromoindole-3-acetamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromoindole-3-acetamide
CAS number: 196081-79-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9BrN2O
Molecular weight: 253.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴吲哚-3-乙酰胺 在 四(三苯基膦)钯 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 2.17h， 生成 2-[5-(3-苯甲基)-1-octyl吲哚-3-基]乙酰胺
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE WITH POTENTIAL ANTICANCER ACTIVITY
  [FR] INHIBITEURS À PETITE MOLÉCULE D'ISOPRÉNYLCYSTÉINE CARBOXYL MÉTHYLTRANFÉRASE AVEC UNE ACTIVITÉ ANTICANCER POTENTIELLE

  摘要：

  本发明通常涉及异戊二烯基半胱氨酸羧甲基转移酶（Icmt）的抑制剂，特别是抑制Icmt活性的化合物及其制药组合物。本发明还涉及使用相同的方法治疗疾病。

  公开号：

  WO2011014128A1
• 作为产物：
  描述：

  5-溴吲哚-3-甲醛 在 sodium tetrahydroborate 、 formamide 、 potassium hydroxide 作用下， 以 甲醇 、 叔丁醇 为溶剂， 反应 6.0h， 生成 5-溴吲哚-3-乙酰胺
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE WITH POTENTIAL ANTICANCER ACTIVITY
  [FR] INHIBITEURS À PETITE MOLÉCULE D'ISOPRÉNYLCYSTÉINE CARBOXYL MÉTHYLTRANFÉRASE AVEC UNE ACTIVITÉ ANTICANCER POTENTIELLE

  摘要：

  本发明通常涉及异戊二烯基半胱氨酸羧甲基转移酶（Icmt）的抑制剂，特别是抑制Icmt活性的化合物及其制药组合物。本发明还涉及使用相同的方法治疗疾病。

  公开号：

  WO2011014128A1

文献信息

• Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
  作者：Duncan A. Hay、Oleg Fedorov、Sarah Martin、Dean C. Singleton、Cynthia Tallant、Christopher Wells、Sarah Picaud、Martin Philpott、Octovia P. Monteiro、Catherine M. Rogers、Stuart J. Conway、Timothy P. C. Rooney、Anthony Tumber、Clarence Yapp、Panagis Filippakopoulos、Mark E. Bunnage、Susanne Müller、Stefan Knapp、Christopher J. Schofield、Paul E. Brennan

  DOI：10.1021/ja412434f

  日期：2014.7.2

  compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues, selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (Kd

  缺乏针对溴结构域和末端外 (BET) 亚家族之外的溴结构域的小分子抑制剂。在这里，我们描述了人类赖氨酸乙酰转移酶 CBP/p300 溴结构域模块的高效和选择性配体，由一系列 5-异恶唑基苯并咪唑开发而成。我们的出发点是片段命中，使用 Suzuki 偶联、苯并咪唑形成反应和还原胺化的平行合成将其优化为更有效和选择性更强的先导化合物。使用热稳定性测定法研究了先导化合物对其他溴结构域家族成员的选择性，结果显示对结构相关的 BET 家族成员有一些抑制作用。为了解决 BET 选择性问题，与 CREB ​​结合蛋白 (CBP) 和 BRD4 的第一个溴结构域 (BRD4(1)) 结合的先导化合物的 X 射线晶体结构用于指导更具选择性的化合物的设计。获得的晶体结构揭示了两种不同的结合模式。通过改变芳基取代模式和开发构象受限的类似物，增加了 CBP 超过 BRD4(1) 的选择性。优化后的化合物具有高效 (Kd
• Amino Derivatives of Indole As Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase
  作者：Mei-Lin Go、Jo Lene Leow、Suresh Kumar Gorla、Andreas Peter Schüller、Mei Wang、Patrick J. Casey

  DOI：10.1021/jm1002843

  日期：2010.10.14

  The enzyme isoprenylcysteine carboxyl methyltransferase (Icmt) plays an important role in the post-translational modification of proteins that are involved in the regulation of cell growth. The indole acetamide cysmethynil is by far the most potent and widely investigated Icmt inhibitor, but it has modest antiproliferative activity and may have pharmacokinetic limitations due to its lipophilic character

  异戊烯基半胱氨酸羧基甲基转移酶（Icmt）在参与细胞生长调节的蛋白质的翻译后修饰中起着重要作用。吲哚乙酰胺氰菊酯是迄今为止最有效和研究最广泛的Icmt抑制剂，但它具有适度的抗增殖活性，并且由于其亲脂性而可能具有药代动力学限制。我们在这里报告说，可以将cysmethynil进行结构修饰，以产生与抑制Icmt一样有效但具有显着更大的抗增殖活性的类似物。关键的修饰是用叔氨基取代乙酰胺侧链，用异戊二烯基取代正辛基侧链，然后用5- m-甲苯基环被氟取代。而且，这些类似物具有较低的亲脂性，这可以导致改善的药代动力学特征。
• Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles
  作者：Thomas A. Engler、Kelly Furness、Sushant Malhotra、Concha Sanchez-Martinez、Chuan Shih、Walter Xie、Guoxin Zhu、Xun Zhou、Scott Conner、Margaret M. Faul、Kevin A. Sullivan、Stanley P. Kolis、Harold B. Brooks、Bharvin Patel、Richard M. Schultz、Tammy B. DeHahn、Kashif Kirmani、Charles D. Spencer、Scott A. Watkins、Eileen L. Considine、Jack A. Dempsey、Catherine A. Ogg、Nancy B. Stamm、Bryan D. Anderson、Robert M. Campbell、Vasu Vasudevan、Michelle L. Lytle

  DOI：10.1016/s0960-894x(03)00461-x

  日期：2003.7

  The synthesis and CDK inhibitory properties of a series of indolo[6,7-a]pyrrolo[3,4-c]carbazoles is reported. In addition to their potent CDK activity, the compounds display antiproliferative activity against two human cancer cell lines. These inhibitors also effect strong G1 arrest in these cell lines and inhibit Rb phosphorylation at Ser780 consistent with inhibition of cyclin D1/CDK4.

  报道了一系列吲哚[6，7-a]吡咯并[3，4-c]咔唑的合成和CDK抑制性能。这些化合物除了具有强大的CDK活性外，还具有针对两种人类癌细胞系的抗增殖活性。这些抑制剂还影响这些细胞系中的强G1阻滞，并抑制Ser780处的Rb磷酸化，这与抑制细胞周期蛋白D1 / CDK4一致。
• COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：US20150328208A1

  公开（公告）日：2015-11-19

  The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

  本发明提供了治疗细胞增殖紊乱（如癌症）的方法，通过向需要的受试者投予一种吡啶喹啉基吡咯-2,5-二酮化合物或吡啶喹啉基吡咯啉-2,5-二酮化合物的治疗有效量，与第二种抗增殖剂的治疗有效量结合使用。
• Macrolide antibiotics
  申请人：——

  公开号：US20040077557A1

  公开（公告）日：2004-04-22

  The present invention relates to 11,12 &ggr; lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及公式（I）中的11,12 &ggr;内酯酮类化合物，其中R、R1、R2、R3如本文所定义的，以及其药学上可接受的盐和溶剂化物，以及它们的制备方法及在人或动物体内治疗或预防全身或局部细菌感染中的应用。